Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Sunday, June 1, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, and other health care providers involved in the treatment and management of small cell lung cancer (SCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss current trial data describing novel strategies for the management of limited- and extensive-stage SCLC
- Apply clinical trial evidence supporting the efficacy and safety of SCLC treatment across lines of care in real-world case-based scenarios
- Plan proactive strategies to mitigate and manage treatment-related adverse events in patients with SCLC
Jonathan W. Goldman, MD
Professor of Medicine, Division of Hematology & Oncology
Director of Clinical Trials in Thoracic Oncology
Associate Director of Drug Development
University of California, Los Angeles
Santa Monica, CA
Disclosures: Consultant: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen, Pfizer, Summit; Grant/Research Support: AbbVie, Agenus, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Genentech, GSK, Janssen, Merck, Pfizer, Puma, RayzeBio, Summit, Tango
Percy Lee, MD, FASTRO
Medical Director, Orange County and Coastal Regions
Department of Radiation Oncology
City of Hope National Medical Center
Irvine, CA
Disclosures: Advisory Board: AstraZeneca, Johnson & Johnson; Consultant: AstraZeneca, Genentech, Johnson & Johnson, Roche; Grant/Research Support: AstraZeneca; Honoraria Recipient: AstraZeneca, Genentech, Johnson & Johnson, Roche
Erminia Massarelli, MD, PhD, MS
Division Chief of Hematology/Oncology
Professor of Medicine
University of Texas at Tyler School of Medicine
Tyler, TX
Disclosures: Adviser: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Johnson & Johnson/Janssen, Sanofi; Consultant; AbbVie
Misty D. Shields, MD, PhD
Assistant Professor of Clinical Medicine
Adjunct Assistant Professor of Medical and Molecular Genetics
Associate Member, Experimental and Developmental Therapeutics
Department of Medicine, Division of Hematology/Oncology, Thoracic Oncology
Melvin & Bren Simon Comprehensive Cancer Center
Indiana University School of Medicine
Indianapolis, IN
Disclosures: Advisory Board: AstraZeneca; Speakers’ Bureau: Jazz Pharmaceuticals; Steering Committee: AstraZeneca
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
